SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing significant activity as President Trump's announcement of a Greenland "framework" and the suspension of EU tariffs fueled a rapid market rebound. Traders are actively discussing the "TACO trade," where initial geopolitical uncertainty quickly reversed, leaving bears burned and reinforcing the "buy the dip" strategy amidst perceived market manipulation. This volatility underscores how headline-driven events continue to create dramatic swings in market sentiment.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending sharply higher after President Trump announced a "framework" deal with NATO regarding Greenland and unexpectedly reversed course on potential new tariffs against Europe. This geopolitical de-escalation is sparking a significant market rally, with many traders labeling it a "TACO" (Trump Always Chickens Out) trade as market fears rapidly dissipate. Community discussion highlights the immediate bullish reaction, while some question the broader implications of such swift policy reversals on market stability.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a new licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community sees as a major validation for its platform. Investors are keenly discussing the potential for a substantial short squeeze, fueled by high short interest and expectations of more partnerships for Matrix-M as a multi-billion dollar asset.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market attention following recent Saudi FDA approval for its Anktiva lung cancer treatment and ongoing dialogue with the FDA for a bladder cancer resubmission. The community is intensely focused on the escalating cost to borrow and diminishing share availability, widely anticipating a massive short squeeze that could propel the stock higher. Many investors are actively "loading the boat," confident in the company's cancer immunotherapy advancements and viewing current market dynamics as a temporary battle against "trapped" short sellers.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is generating significant buzz as investors keenly follow recent U.S. regulatory updates, including streamlined deep-sea mining permit processes and an upcoming Congressional hearing featuring TMC's CEO. The community anticipates a major breakout, driven by increasing recognition of deep-sea minerals as a national security priority and the potential for expedited commercial recovery.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively discussed amidst evolving geopolitical developments surrounding Greenland's rare earth mineral rights, particularly following recent statements from former President Trump and upcoming business updates. Investors are closely watching for definitive outcomes, with many anticipating a significant boost from any potential deal securing U.S. access to Greenland's vast critical metal deposits, despite notable short-term volatility and accusations of market manipulation.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is trending following news that its subsidiary, Lucid Diagnostics, has secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, broadening access to precancer screening. This development, combined with the stock's low float, is fueling intense community discussion about a potential short squeeze and substantial upside, although some express concerns about possible dilution.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending due to a significant partnership with Primary Digital Infrastructure for a massive AI data center campus in West Texas, coupled with a key acquisition. The community is actively discussing strong price action and anticipating an imminent announcement regarding a hyperscaler tenant, fueling speculation of continued upward momentum and a potential short squeeze within the burgeoning AI infrastructure sector.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant volatility following Donald Trump's comments from Davos, which included remarks on tariffs and crypto legislation. The community remains fiercely divided, with some anticipating a major short squeeze and new all-time highs, while others warn of institutional manipulation and potential bear traps amid the turbulent price action.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is fueling intense market debate following an extraordinary, near-parabolic rally driven by surging demand for memory and data storage, particularly from the AI infrastructure sector, amidst tight supply. While many celebrate its astronomical gains and anticipate further upside, a vocal group warns of an unsustainable bubble nearing a dramatic correction. The divergence of opinion creates a highly charged environment as traders watch for signs of exhaustion or continued momentum.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why

Caribou Biosciences (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cathie Wood shells out $1.3 million on biotech stock

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it...

Caribou Biosciences (NASDAQ:CRBU) Trading Up 2.4% - Should You Buy?

Caribou Biosciences (NASDAQ:CRBU) Trading 2.4% Higher - Here's Why...

Caribou Biosciences Target of Unusually Large Options Trading (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) was the recipient of some unusual options trading on Monday. Investors purchased 2,867 call options on the stock. This represents an increase...

Caribou Biosciences, Inc. $CRBU Shares Bought by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 626.8% in the 2nd quarter, according to its most recent Form 13F filing with the...

Caribou Biosciences (NASDAQ:CRBU) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus...

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -147.37% and -71.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Brookline Capital Management Predicts CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Analysts at Brookline Capital Management dropped their FY2026 earnings per share (EPS) estimates for Caribou Biosciences in a research note...

<p>Shares of Caribou Biosciences, Inc. (CRBU) jumped 52% in the pre-market session on Monday after the company announced positive data from early-stage trials of two of its CAR-T cell therapies.</p><p>While one of the therapies was evaluated for the treatment of multiple myeloma, a blood cancer of plasma cells, the other was assessed in B-cell non-Hodgkin lymphoma (NHL), a cancer that originates in B lymphocytes, a type of white blood cell that fights infection.</p><h2 class="st-heading-2">Study In Multiple Myeloma</h2><p>The company said that the first clinical data for its CB-011 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179047/0/en/Caribou-Biosciences-Announces-Positive-Data-from-CaMMouflage-Phase-1-Trial-of-CB-011-in-Multiple-Myeloma.html">highlights</a> its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.</p><p>The company now expects to advance the program into the dose expansion phase by the end of the year. In the dose escalation portion of the trial, CB-011 had a manageable safety profile across all dose levels, the company noted. The portion of the trial evaluated the safety and efficacy of CB-011 in 48 patients at multiple dose levels and following two different chemotherapy treatments.</p><h2 class="st-heading-2">Study In B-cell non-Hodgkin lymphoma</h2><p>Meanwhile, data from an early-stage trial of vispacabtagene regedleucel (Vispa-cel) demonstrated the efficacy and durability of the cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3179104/0/en/Caribou-Biosciences-Announces-Positive-Data-from-ANTLER-Phase-1-Trial-Demonstrating-Efficacy-and-Durability-of-Vispa-cel-CB-010-an-Allogeneic-CAR-T-Cell-Therapy-on-Par-with-Autolog.html">said</a>. Vispa-cel was generally well-tolerated, allowing for administration in the outpatient setting, the company added.</p><p>“We believe that with these results, Caribou has achieved what the field has long sought — strong evidence that an allogeneic CAR-T cell therapy can be on par with the efficacy and durability of autologous treatments and broaden access with a safety profile that allows for outpatient use,” said CEO Rachel Haurwitz.</p><p>Allogeneic CAR-T cell therapy is a type of "off-the-shelf" cancer treatment that uses T-cells from a healthy donor, rather than the patient's own cells, allowing immediate availability. Autologous therapy, however, uses a patient's own cells or tissues, which are collected, processed outside the body, and then reintroduced to the same individual.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRBU">CRBU stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.</p><p>CRBU stock is up 52% this year and approximately 3% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-sales-in-us-rise-1.6-percent-in-october/cL2NX8OR3CR">Ford Sales In US Rise 1.6% In October On Continued Truck Demand</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Rising stock market chart on a trading board background.

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For  Cancer Treatments

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 

Equity

The company announced positive data from trials of CB-011 and Vispa-cel in relapsed or refractory multiple myeloma and B-cell non-Hodgkin lymphoma, respectively. 


Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Caribou Biosciences Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$1.49
Prev Close	$1.39
Open	$1.41
Dividend Yield	0.00%
50-Day Moving Average	$1.78
Beta	1.84
Avg. Volume	988,999.14
PE Ratio	-0.82

52-Week High	$3.54
52-Week Low	$0.66
Market Capitalization	$129.92M
EPS (Annual)	-$1.65
Price to Book	0.92
Revenue Per Employee	$67,986.40
Enterprise Value/EBITDA	N/A

CRBU
Caribou Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBU News

CRBUCaribou Biosciences Inc